LifeTech Scientific Corporation
先 健 科 技 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

FINANCIAL HIGHLIGHTS

- The revenue for the six months ended 30 June 2026 was approximately RMB600.8 million, representing a decrease of approximately 11.2% as compared with the revenue of approximately RMB676.7 million for the six months ended 30 June 2025. Gross profit for the six months ended 30 June 2026 was approximately RMB465.9 million, representing a decrease of approximately 6.4% as compared with the gross profit of approximately RMB497.8 million for the six months ended 30 June 2025.

- Net profit attributable to owners of the Company for the six months ended 30 June 2026, excluding certain non-recurring items as set out below, was approximately RMB114.8 million as compared with the net profit amounting to approximately RMB238.5 million for the six months ended 30 June 2025, representing a decrease of approximately 51.9%. The decrease was mainly due to (i) a decrease in revenue, which amounted to approximately RMB75.9 million; and (ii) a decrease in net exchange gains, which amounted to approximately RMB56.8 million (net exchange losses of approximately RMB32.8 million for the six months ended 30 June 2026, as compared with net exchange gains of approximately RMB24.0 million in the corresponding period of 2025).

- The above-mentioned non-recurring items include (i) the other losses arising from financial assets at fair value through profit or loss ("FVTPL") of approximately RMB0.8 million for the six months ended 30 June 2026 (corresponding period of 2025: gains of approximately RMB9.9 million); (ii) the share-based payment expenses of approximately RMB123.1 million for the six months ended 30 June 2026 (corresponding period of 2025: approximately RMB193.5 million); and (iii) the transaction expenses in connection with a proposed transaction involving the conditional acquisition of equity interest in Starway Medical Technology, Inc. (北京華醫聖傑科技有限公司) ("Starway") and the issue of convertible bonds, which the Board has resolved not to proceed with, amounting to approximately RMB25.3 million (corresponding period of 2025: nil). Taking into account the effects of such non-recurring items, the net loss attributable to owners of the Company for the six months ended 30 June 2026 was approximately RMB34.3 million, representing a decrease of approximately 162.3% as compared with net profit of approximately RMB55.1 million for the six months ended 30 June 2025.

- The Board did not recommend the payment of any interim dividends for the six months ended 30 June 2026 (corresponding period of 2025: nil).

UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

The board (the "Board") of directors (the "Directors", each a "Director") of LifeTech Scientific Corporation (the "Company" or "Lifetech") is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 June 2026 (the "Reporting Period") together with the comparative figures for the corresponding period of 2025.

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2026

	NOTES	**Six months ended 30 June** **2026** **RMB'000** **(Unaudited)**	2025 RMB'000 (Unaudited)
Revenue	4	**600,830**	676,707
Cost of sales		**(134,934)**	(178,952)
Gross profit		**465,896**	497,755
Other income, expenses, gains and losses	5	**(19,679)**	50,365
Selling and distribution expenses		**(178,080)**	(250,905)
Administration expenses		**(147,230)**	(118,369)
Research and development expenses		**(132,163)**	(114,459)
Operating (loss) profit		**(11,256)**	64,387
Finance income, net		**2,499**	10,122
Share of (losses) gains of associates		**(3,021)**	5,291
(Loss) profit before tax	6	**(11,778)**	79,800
Income tax expense	7	**(36,505)**	(38,035)
(Loss) profit for the period		**(48,283)**	41,765
Other comprehensive (expense) income:			
Items that will not be reclassified to profit or loss:			
Fair value (loss) gain and exchange differences on investments in equity instruments at fair value through other comprehensive income ("FVTOCI"), net of tax		**(9,834)**	26,311
Items that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation of foreign operations		**1,901**	(614)
Other comprehensive (expense) income for the period		**(7,933)**	25,697
Total comprehensive (expense) income for the period		**(56,216)**	67,462
(Loss) profit for the period attributable to:			
Owners of the Company		**(34,348)**	55,074
Non-controlling interests		**(13,935)**	(13,309)
		(48,283)	41,765
Total comprehensive (expense) income attributable to:			
Owners of the Company		**(42,281)**	80,771
Non-controlling interests		**(13,935)**	(13,309)
		(56,216)	67,462
(Loss) earnings per share	9		
– Basic (RMB cents)		**(0.8)**	1.3
– Diluted (RMB cents)		**(0.8)**	1.3

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

	NOTES	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Non-current assets			
Property, plant and equipment		**907,523**	921,096
Right-of-use assets		**47,625**	47,410
Investment properties		**288,383**	290,578
Intangible assets		**800,488**	779,184
Interests in associates		**97,580**	106,340
Financial assets at FVTPL	10	**352,995**	353,797
Equity instruments at FVTOCI	11	**35,557**	45,391
Deposits for acquisition of property, plant and equipment		**15,672**	17,922
Deferred tax assets		**133,242**	125,576
		2,679,065	2,687,294
Current assets			
Inventories		**421,972**	444,903
Trade receivables	12	**122,028**	161,797
Other receivables and prepayments	13	**287,609**	515,380
Financial assets at FVTPL	10	**143,000**	401,000
Fixed bank deposits		**139,314**	29,783
Restricted bank deposits		**2,615**	52,956
Cash and cash equivalents		**953,772**	719,315
		2,070,310	2,325,134
Current liabilities			
Trade and other payables	14	**788,935**	841,070
Contract liabilities		**9,452**	31,247
Tax liabilities		**37,387**	26,551
Lease liabilities		**4,072**	3,761
Financial liabilities at FVTPL	15	**—**	576,779
Bank borrowing	16	**5,000**	—
		844,846	1,479,408
Net current assets		**1,225,464**	845,726
Total assets less current liabilities		**3,904,529**	3,533,020

	NOTES	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Non-current liabilities			
Government grants		**54,172**	53,636
Lease liabilities		**5,026**	4,276
Financial liabilities at FVTPL	15	**576,779**	—
		635,977	57,912
Net assets		**3,268,552**	3,475,108
Capital and reserves			
Share capital	17	**37**	37
Reserves		**3,319,352**	3,512,610
Equity attributable to owners of the Company		**3,319,389**	3,512,647
Non-controlling interests		**(50,837)**	(37,539)
Total equity		**3,268,552**	3,475,108

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2026

1. GENERAL INFORMATION

The Company was incorporated in the Cayman Islands on 17 August 2006 as an exempted company with limited liability and its shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). Mr. XIE Yuehui, is the Chairman and Chief Executive Officer of the Company. The address of the registered office is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and the address of the principal place of business is LifeTech Scientific Building, No.22, Keji 12th Road South, High-tech Industrial Park, Nanshan District, Shenzhen, Guangdong Province, the People's Republic of China (the "PRC").

The Company is an investment holding company. The principal activities of the Group are developing, manufacturing and trading of advanced interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.

The condensed consolidated financial statements are presented in Renminbi ("RMB"), which is the functional currency of the Company and the Group's major operating subsidiaries.

2. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements of the Group for the six months ended 30 June 2026 have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" issued by the International Accounting Standards Board ("IASB") as well as with the applicable disclosure requirements of Appendix D2 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

3. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair value.

The accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2026 are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2025.

In addition, in the current interim period, the Group has applied a new interpretation and certain amendments to International Financial Reporting Standards ("IFRSs") issued by the IASB that are mandatorily effective for the current interim period. The application of the above new interpretation and amendments to IFRSs in the current interim period has had no material effect on the amounts reported in these condensed consolidated financial statements and/or disclosures set out in these condensed consolidated financial statements.

4. **SEGMENT INFORMATION**

The segment information reported internally was analysed on the basis of their products supplied by the Group's operating divisions which is consistent with the internal information that is regularly reviewed by executive Directors of the Company, the chief operating decision makers, for the purposes of resource allocation and assessment of performance.

The Group's operating segments under IFRSs 8 are as follows:

- Structural heart diseases business: trade, manufacture, research and development of devices related to structural heart diseases.
- Peripheral vascular diseases business: trade, manufacture, research and development of devices related to peripheral vascular diseases.
- Cardiac pacing and electrophysiology business: trade, manufacture, research and development of devices related to cardiac pacing and electrophysiology.

Information regarding the above segments is reported below.

(A) SEGMENT REVENUE AND RESULTS

The following is an analysis of the Group's revenue and results by operating and reportable segments:

For the six months ended 30 June 2026

	Structural heart diseases business RMB'000 (Unaudited)	Peripheral vascular diseases business RMB'000 (Unaudited)	Cardiac pacing and electrophysiology business RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
SEGMENT REVENUE				
External sales	200,082	400,748	—	600,830
Segment profit	178,882	287,014	—	465,896
Unallocated income				
– Other income and other gains				26,303
– Finance income				2,689
Unallocated expense				
– Selling and distribution expenses				(178,080)
– Administration expenses				(147,230)
– Research and development expenses				(132,163)
– Other expenses and losses				(45,982)
– Finance costs				(190)
– Share of losses of associates				(3,021)
Losses before tax				(11,778)

For the six months ended 30 June 2025

	Structural heart diseases business RMB'000 (Unaudited)	Peripheral vascular diseases business RMB'000 (Unaudited)	Cardiac pacing and electrophysiology business RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
SEGMENT REVENUE				
External sales	271,539	391,693	13,475	676,707
Segment profit	237,686	258,214	1,855	497,755
Unallocated income				
– Other income and other gains				63,730
– Finance income				10,257
– Share of gains of associates				5,291
Unallocated expense				
– Selling and distribution expenses				(250,905)
– Administration expenses				(118,369)
– Research and development expenses				(114,459)
– Other expenses and losses				(13,365)
– Finance costs				(135)
Profit before tax				79,800

Segment profit represents the gross profit earned by each segment without allocation of all other items of income and expenses, as set out above. This is the measure reported to the chief operating decision makers, the executive Directors of the Company, for the purposes of resources allocation and assessment of segment performance.

(B) SEGMENT ASSETS AND LIABILITIES

The following is an analysis of the Group's assets and liabilities by operating and reportable segments:

SEGMENT ASSETS

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Operating segments:		
Structural heart diseases business	**586,213**	618,308
Peripheral vascular diseases business	**1,174,187**	1,020,646
Cardiac pacing and electrophysiology business	**45,632**	70,595
Total segment assets	**1,806,032**	1,709,549
Unallocated assets		
Interests in associates	**97,580**	106,340
Property, plant and equipment	**402,158**	553,963
Right-of-use assets	**47,625**	47,410
Investment properties	**288,383**	290,578
Deferred tax assets	**133,242**	125,576
Financial assets at FVTPL	**495,995**	754,797
Equity instruments at FVTOCI	**35,557**	45,391
Other receivables and prepayments	**287,609**	515,380
Cash and cash equivalents	**953,772**	719,315
Restricted bank deposits	**2,615**	52,956
Fixed bank deposits	**139,314**	29,783
Intangible assets	**43,821**	43,468
Deposits for acquisition of property, plant and equipment	**15,672**	17,922
Consolidated assets	**4,749,375**	5,012,428

SEGMENT LIABILITIES

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Operating segments:		
Structural heart diseases business	**111,570**	137,302
Peripheral vascular diseases business	**223,476**	226,646
Cardiac pacing and electrophysiology business	**27,099**	22,733
Total segment liabilities	**362,145**	386,681
Unallocated liabilities		
Other payables	**434,858**	482,312
Lease liabilities	**9,098**	8,037
Bank borrowing	**5,000**	—
Tax liabilities	**37,387**	26,551
Government grants	**55,556**	56,960
Financial liabilities at FVTPL	**576,779**	576,779
Consolidated liabilities	**1,480,823**	1,537,320

For the purposes of monitoring segment performances and allocating resources between segments:

- All assets are allocated to operating segments other than interests in associates, certain property, plant and equipment, right-of-use assets, investment properties, deferred tax assets, financial assets at FVTPL, equity instruments at FVTOCI, other receivables and prepayments, cash and cash equivalents, fixed bank deposits, restricted bank deposits, certain intangible assets and deposits for acquisition of property, plant and equipment; and

- All liabilities are allocated to operating segments in arriving at segment liabilities, which exclude certain other payables, bank borrowing, tax liabilities, government grants (include current portion under other payables and non-current portion), lease liabilities and financial liabilities at FVTPL.

5. OTHER INCOME, EXPENSES, GAINS AND LOSSES

	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Other income and expenses		
Government grants	**3,642**	7,989
Rental income generated from investment properties	**17,112**	17,712
Depreciation of investment properties	**(4,944)**	(4,722)
Others	**(1,844)**	(4,246)
	13,966	16,733
Other gains and losses		
Losses on disposal of property, plant and equipment and intangible assets	**(33)**	(269)
Gains from changes in fair value of hybrid funds	**1,783**	13,996
Gains (losses) from changes in fair value of equity funds	**3,766**	(3,260)
Unrealised foreign exchange losses in financial assets at FVTPL	**(6,351)**	(868)
Other net foreign exchange (losses) gains	**(32,810)**	24,033
	(33,645)	33,632
	(19,679)	50,365

6. (LOSS) PROFIT BEFORE TAX

	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
(Loss) profit before tax has been arrived at after charging (crediting):		
Staff costs, including Directors' remuneration		
Directors' fees	**315**	360
Salaries, wages, performance related bonus and other benefits	**196,202**	168,296
Share-based payment expenses	**123,058**	193,500
Retirement benefits scheme contributions	**18,902**	18,658
Less: capitalised in development costs, construction in progress and inventories	**(20,949)**	(21,238)
	317,528	359,576
Cost of inventories recognised as expenses	**134,934**	178,952
Depreciation of property, plant and equipment	**30,714**	26,415
Depreciation of right-of-use assets	**3,361**	2,678
Depreciation of investment properties	**4,944**	4,722
Amortisation of intangible assets	**13,701**	8,935
Total depreciation and amortisation	**52,720**	42,750
Gross rental income from investment properties	**(17,112)**	(17,712)
Less: direct operating expenses incurred for investment properties that generated rental income during the period	**4,944**	4,722
	(12,168)	(12,990)

7. INCOME TAX EXPENSE

	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Current tax charge:		
PRC Enterprise Income Tax ("PRC EIT")	**26,003**	30,415
Hong Kong Profits Tax	**18,168**	8,530
Deferred tax credit:		
Current period	**(7,666)**	(910)
	36,505	38,035

The Company is tax exempted under the laws of the Cayman Islands.

Lifetech Scientific International Holding Limited, a subsidiary of the Company, is subject to Hong Kong Profits Tax. On 21 March 2018, the Hong Kong Legislative Council passed The Inland Revenue (Amendment) (No. 7) Bill 2018 (the "Bill") which introduced the two-tiered profits tax rates regime. The Bill was signed into law on 28 March 2018 and was gazetted on the following day. Under the two-tiered profits tax rates regime, the first HKD2.0 million of profits of the qualifying group entity will be taxed at 8.25%, and profits above HKD2.0 million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5% on assessable profits earned in Hong Kong.

Under the Law of the PRC on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% except for Lifetech Scientific Shenzhen Co., Ltd. (先健科技(深圳)有限公司) ("Lifetech Shenzhen"), the major operating subsidiary in the PRC. Lifetech Shenzhen has been qualified as a High and New Technology Enterprise since 2009, which was subsequently renewed in November 2023, and therefore Lifetech Shenzhen is entitled to a preferential corporate income tax rate of 15% for each of the six months ended 30 June 2025 and 30 June 2026. Biotyx Medical (Shenzhen) Co., Ltd. (元心科技(深圳)有限公司) ("Biotyx Medical"), a subsidiary of Lifetech Shenzhen, was qualified as High and New Technology Enterprise since 2021, which was subsequently renewed in December 2025, and therefore Biotyx Medical is entitled to a preferential income tax rate of 15% for the six months ended 30 June 2026. The qualification of High and New Technology Enterprises is subject to review by relevant authorities in the PRC for every three years.

The applicable income tax rate of Lifetech Scientific India Private Ltd. in the jurisdiction of India is 30.9% on its taxable profits. No provision for taxation in India has been made as there is no assessable profits in India for both periods.

Taxation arising in other jurisdictions is calculated at the rates prevailing in the relevant jurisdictions.

8. DIVIDENDS

No dividend was paid, declared or proposed during the interim periods ended 30 June 2026 and 2025, nor has any dividend been proposed since the end of the Reporting Period.

9. (LOSS) EARNINGS PER SHARE

The calculation of basic and diluted loss/earnings per share attributable to the owners of the Company is based on the following data:

	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
(Loss) earnings:		
(Loss) earnings for the purposes of basic and diluted loss/earnings per share	**(34,348)**	55,074

	Six months ended 30 June	
	2026	2025
	'000	'000
	(Unaudited)	(Unaudited)
Number of shares:		
Weighted average number of ordinary shares for the purpose of basic loss/earnings per share (Note)	**4,383,710**	4,344,028
Effect of dilutive potential ordinary shares:		
Share options	**—**	130
Award shares	**19,712**	6,490
Weighted average number of ordinary shares for the purpose of diluted loss/earnings per share (Note)	**4,403,422**	4,350,648

The computation of diluted loss/earnings per share does not assume the conversion of certain of the Company's share options because the exercise price of those options was higher than the average market prices for shares for the six months ended 30 June 2026 and 2025.

Note: Treasury shares are deducted from total number of shares in issue for the purpose of calculating loss/earnings per share.

10. FINANCIAL ASSETS AT FVTPL

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Financial assets mandatorily measured at FVTPL:		
Non-current assets		
Unlisted funds		
– Equity funds (Note i)	**202,290**	204,875
– Hybrid funds (Note ii)	**50,625**	48,842
Investment in an associate held via preference shares (Note iii)	**100,000**	100,000
Others	**80**	80
	352,995	353,797
Current assets		
Short-term bank structured deposits (Note iv)	**143,000**	401,000

Notes:

(i) On 25 May 2018, the Group entered into a subscription agreement with certain independent third parties pursuant to which the Group agreed to subscribe for interest of a private equity fund ("2018 Equity Fund"), as a limited partner, for an aggregate consideration of USD6,000,000 (equivalent to approximately RMB38,202,000) in cash. The 2018 Equity Fund principally invests in securities or assets of companies that are involved in the healthcare industry, with a particular focus on cross-border innovative late-stage venture opportunities and crossover investments.

On 24 October 2022, the Group entered into a subscription agreement with certain independent third parties pursuant to which the Group agreed to subscribe for interest of a private equity fund ("2022 Equity Fund"), as a limited partner, for an aggregate consideration of USD20,000,000 (equivalent to approximately RMB144,378,000) in cash. The purposes of the 2022 Equity Fund are to seek capital appreciation primarily by acquiring, holding and disposing of securities, independently or with others, primarily in non-listed or, sometimes, listed persons involved in the healthcare industry, with a particular focus on leading innovative technologies.

The Group holds approximately 9.69% (31 December 2025: approximately 9.69%) and approximately 4.60% (31 December 2025: approximately 4.60%) interest respectively in the 2018 Equity Fund and 2022 Equity Fund as at 30 June 2026.

(ii) On 8 January 2021, the Group entered into a contract to purchase a hybrid fund unit with a financial institution, which was accounted for as financial assets at FVTPL on initial recognition, for a consideration of RMB10,000,000 in cash.

On 28 November 2023, the Group entered into a contract to purchase another hybrid fund unit with a financial institution, which was accounted for as financial assets at FVTPL on initial recognition, for a consideration of RMB50,000,000 in cash.

(iii) On 6 June 2025, the Group entered into a series of agreements through Lifetech Shenzhen, to make a cash investment in Affector Medtech (Suzhou) Ltd. (劍虎醫療科技(蘇州)有限公司) ("Affector Medtech"), for a total consideration of RMB150,000,000. Upon completion of all stages of the investment, Lifetech Shenzhen will hold 30% equity interest in Affector Medtech.

As at 31 December 2025 and 30 June 2026, Lifetech Shenzhen has completed the first stage of capital injection, for a consideration of RMB100,000,000 in cash and holds a 22.22% equity interest in Affector Medtech.

The Group is able to exercise significant influence over Affector Medtech because the Group is entitled to appoint two of the seven directors under the articles of association of Affector Medtech. Pursuant to the above mentioned agreements, if Affector Medtech is unable to meet certain specified conditions under agreed milestone, Lifetech Shenzhen will have the right to exercise the liquidation preference and redemption rights. Taking into account the substantive redemption and liquidation preference features, the Directors of the Company consider these preferred shares do not carry rights that are substantially the same as the Affector Medtech's ordinary shares and accordingly these preferred shares are accounted for as financial instruments measured at FVTPL under IFRS 9.

In the opinion of the directors of the Company, the investment is held for long-term strategic investment purposes and as such, the investment is classified as non-current asset. In the opinion of the directors of the Company, the fair value change in relation to the investment during the six months ended 30 June 2026 is insignificant.

(iv) As at 30 June 2026, the Group had short-term bank structured deposits of RMB143.0 million (31 December 2025: RMB401.0 million).

The above equity funds are managed by fund/investment managers, and the Group does not have rights to engage in the management of the equity funds. The Group, as a limited partner in the equity funds does not have the rights to participate in the financial and operating policy decisions of the equity funds. As such, the Group does not have significant influence over the equity funds, and therefore they are not accounted for as associates.

The equity funds and hybrid funds are accounted for as financial assets at FVTPL in accordance with IFRS 9. In the opinion of the Directors of the Company, these funds are held for long-term strategic investment purposes and as such, the investments are classified as non-current assets.

11. EQUITY INSTRUMENTS AT FVTOCI

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Listed:		
– Equity securities listed in Hong Kong (Note)	**35,557**	45,391

Note:

On 21 September 2022, the Group entered into a subscription agreement with Jenscare Scientific Co., Ltd. (寧波健世科技股份有限公司) ("Jenscare Scientific") pursuant to which the Group agreed to subscribe for shares of Jenscare Scientific upon the initial public offering, as a cornerstone investor, for an aggregate consideration of USD20,000,000 (equivalent to approximately RMB143,947,000) in cash with the subscription price of HKD27.8 per share. There is a lock-up period of six months upon the initial public offering on 10 October 2022.

In the opinion of the Directors of the Company, the investment is held for long-term strategic investment purposes and as such, it is classified as non-current asset.

12. TRADE RECEIVABLES

The Group normally allows a credit period of 30 to 180 days (corresponding period of 2025: 30 to 180 days) to its trade customers. The following is an ageing analysis of trade receivables, net of allowance for credit losses, presented based on the invoice dates at the end of the Reporting Period, which approximated the respective revenue recognition dates:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
1 - 90 days	**98,340**	147,602
91 - 180 days	**16,055**	6,795
181 - 365 days	**3,643**	2,900
Over 365 days	**3,990**	4,500
	122,028	161,797

13. OTHER RECEIVABLES AND PREPAYMENTS

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Other debtors (Note i)	**138,645**	123,353
Value added tax deductible	**48,647**	46,306
Prepayments	**58,166**	31,645
Advance to employees - interest free	**37,073**	35,028
Amounts due from directors - others (Note ii)	**—**	274,869
Rental deposits	**1,969**	1,592
Other deposits	**3,109**	2,587
	287,609	515,380

Notes:

(i) These are unsecured and interest-free. In the opinion of the directors, the Group will demand for repayments within one year from the end of the Reporting Period and the amounts are therefore considered as current.

Included in the amount as at 30 June 2026 was the balance to an associate amounting to approximately RMB3,709,000 (31 December 2025: approximately RMB3,313,000).

In addition, the amount as at 31 December 2025 and 30 June 2026 also includes receivables from certain employees, who were appointed as directors of the Company subsequent to the relevant transactions (one of whom resigned from the directorship on 22 May 2026), amounting to approximately RMB66,143,000 (31 December 2025: approximately RMB66,143,000). Such receivables represent amounts advanced by the Company on their behalf and recoverable from them. These receivables are non-trade in nature, unsecured, interest-free and repayable on demand.

(ii) As at 31 December 2024, the amount represents deferred payment from employees of the Group who were granted 230,945,000 shares under the 2019 Share Award Scheme adopted on 28 December 2018 for the purchase price of HKD1.35 per share. The corresponding shares remained at the scheme pending payment. At the time of grant and acceptance of such share awards, none of these employees was a connected person of the Company as defined under the Listing Rules.

On 21 November 2025, these employees were appointed as directors of the Company. During the year ended 31 December 2025, an aggregate of consideration of approximately RMB6,596,000, representing the consideration of 5,409,338 ordinary shares, have been settled by these directors. As at 31 December 2025, the amount due from the directors represents the consideration receivable for the remaining 225,535,662 shares (the "Outstanding Shares").

Subsequently, on 30 March 2026, these directors had irrevocably surrendered and foregone the Outstanding Shares without any recourse against the Company, any of its subsidiaries or any of their respective directors, officers, employees, agents, advisers and other representatives. Accordingly, as at 30 June 2026, the Outstanding Shares were recognised as reserve for share award scheme and the corresponding amount due was offset. This is considered as non-cash transaction of the Company.

14. TRADE PAYABLES

The credit period granted by suppliers to the Group ranged from 30 to 120 days (corresponding period of 2025: 30 to 120 days). The following is an ageing analysis of trade payables presented based on the invoice dates at the end of the Reporting Period:

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
0 - 30 days	**15,537**	10,100
31 - 60 days	**11,657**	11,862
61 - 120 days	**18,264**	21,455
Over 120 days	**41,839**	41,286
	87,297	84,703

15. FINANCIAL LIABILITIES AT FVTPL

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Capital injection from other investors	**576,779**	576,779

During the year ended 31 December 2020, Lifetech Shenzhen, a wholly-owned subsidiary of the Company, entered into a shareholders' agreement ("Series A Agreement") with certain independent third parties for issuance of shares of Biotyx Medical with a total consideration of RMB135,000,000. Pursuant to the Series A Agreement, during the year ended 31 December 2020, Biotyx Medical received the first capital injection of RMB67,500,000. During the year ended 31 December 2021, Biotyx Medical received the second capital injection of RMB67,500,000. Upon the completion of the above transaction, the Group's equity interest in Biotyx Medical decreased from 66.17% to 57.44%.

During the year ended 31 December 2023, Lifetech Shenzhen entered into another shareholders' agreement ("Series B Agreement") with certain independent third parties for issuance of shares of Biotyx Medical, with a total consideration of RMB202,000,000. Pursuant to the Series B Agreement, during the year ended 31 December 2023, Biotyx Medical received the total capital injection of RMB202,000,000. Upon the completion of the above transaction, the Group's equity interest in Biotyx Medical decreased from 57.44% to 49.64%.

During the six months ended 30 June 2026, Lifetech Shenzhen entered into another shareholders' agreement ("Series C Agreement") with certain independent third parties for issuance of shares of Biotyx Medical, with a total consideration of RMB121,546,000. Pursuant to the Series C Agreement, the capital injection is payable upon the satisfaction of certain conditions. As at 30 June 2026, the capital injection had not yet been received. Upon the completion of the above transaction, the Group's equity interest in Biotyx Medical will decrease from 49.64% to 48.13%.

Pursuant to the above mentioned Series A, Series B and Series C Agreements, if Biotyx Medical is unable to meet certain specified conditions within the agreed timeframe, the holders of these shares will have the right to require Biotyx Medical to redeem all of their shares at the predetermined consideration. Accordingly, these shares are classified as a financial liability.

As at 30 June 2026, the above-mentioned agreed timeframe according to Series C Agreement was extended, and therefore the financial liabilities at FVTPL are reclassified as non-current liabilities.

16. BANK BORROWING

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Unsecured bank borrowing	**5,000**	—
The carrying amount of the above borrowing is repayable*:		
Within one year	**5,000**	—
Amount shown under current liabilities	**5,000**	—

* The amount due is based on scheduled repayment date set out in the loan agreement.

17. SHARE CAPITAL

	Number of Shares	Amount USD
Ordinary Shares		
Authorised:		
At 1 January 2025, 31 December 2025 and 30 June 2026 at USD0.00000125 each	40,000,000,000	50,000

	Number of Shares	Amount USD	Shown in the condensed consolidated financial statements as RMB'000
Issued and fully paid:			
At 1 January 2025	4,630,612,400	5,789	37
Exercise of share options	1,100,000	1	— *
At 31 December 2025	4,631,712,400	5,790	37
Exercise of share options	—	—	—
At 30 June 2026	**4,631,712,400**	**5,790**	**37**

* Less than RMB1,000.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS OVERVIEW

The Group is a developer, manufacturer and marketer of advanced minimally invasive interventional medical devices for cardiovascular, peripheral vascular diseases and disorders. We have three main product lines, covering the structural heart diseases business, the peripheral vascular diseases business and the cardiac pacing and electrophysiology business. Structural heart diseases related products mainly include the congenital heart diseases occluders and Left Atrial Appendage ("LAA") occluders; peripheral vascular diseases related products mainly include vena cava filters and stent grafts; and cardiac pacing and electrophysiology related products mainly include cardiac pacemakers. These three product lines provide clinically effective and commercially attractive product offerings. The Group has built a strong sales network globally and has distributors in numerous countries across Asia, Europe, North America, South America and Africa.

FIRST-HALF PERFORMANCE

The Group recorded a revenue of approximately RMB600.8 million for the six months ended 30 June 2026, representing a decrease of approximately RMB75.9 million or approximately 11.2% as compared with the revenue of approximately RMB676.7 million for the corresponding period of 2025. China's mainland remained our largest market, where the revenue generated accounted for approximately 69.6% of our total revenue for the six months ended 30 June 2026 (corresponding period of 2025: approximately 74.1%). Meanwhile, Asia (excluding China's mainland) and Europe were our two largest overseas markets, which accounted for approximately 10.3% and 12.6%, respectively, of our total revenue for the six months ended 30 June 2026 (corresponding period of 2025: approximately 11.4% and 11.0%, respectively). For the six months ended 30 June 2026, domestic sales of the Group decreased by approximately 16.6% as compared with the corresponding period of 2025, while overseas sales of the Group increased by approximately 4.1% (approximately 8.2% in USD). The growth in overseas sales was mainly attributable to the Company's active expansion of overseas business and effective marketing strategies.

Net profit attributable to owners of the Company for the six months ended 30 June 2026, excluding certain non-recurring items as set out below, was approximately RMB114.8 million as compared with the net profit amounting to approximately RMB238.5 million for the six months ended 30 June 2025, representing a decrease of approximately 51.9%. The decrease was mainly due to (i) a decrease in revenue, which amounted to approximately RMB75.9 million; and (ii) a decrease in net exchange gains, which amounted to approximately RMB56.8 million (net exchange losses of approximately RMB32.8 million for the six months ended 30 June 2026, as compared with net exchange gains of approximately RMB24.0 million in the corresponding period of 2025).

The above-mentioned non-recurring items include (i) the other losses arising from financial assets at FVTPL of approximately RMB0.8 million for the six months ended 30 June 2026 (corresponding period of 2025: gains of approximately RMB9.9 million); (ii) the share-based payment expenses of approximately RMB123.1 million for the six months ended 30 June 2026 (corresponding period of 2025: approximately RMB193.5 million); and (iii) the transaction expenses in connection with a proposed transaction involving the conditional acquisition of equity interest in Starway and the issue of convertible bonds, which the Board has resolved not to proceed with, amounting to approximately RMB25.3 million (corresponding period of 2025: nil). Taking into account the effects of such non-recurring items, the net loss attributable to owners of the Company for the six months ended 30 June 2026 was approximately RMB34.3 million, representing a decrease of approximately 162.3% as compared with net profit of approximately RMB55.1 million for the six months ended 30 June 2025.

SALES AND MARKETING

The Group has an experienced team of sales and marketing professionals that are dedicated to support and manage existing distribution networks and to explore new markets. We enhanced the brand awareness and influence of our products by organizing or participating in domestic and international medical conferences, academic activities, seminars, live broadcasts of surgical procedures and delivering trainings to medical professionals. Meanwhile, the Lifetech Knowledge Exchange Program connected cardiovascular experts around the world for academic exchanges. These experts exchanged valuable medical experience and clinical skills which were highly conducive to promoting the development of medical technology in the field of minimally invasive cardiovascular interventions. Such activities showcased our strengths in product innovation and helped enhance the Company's sales and influence in the international medical community.

RESEARCH AND DEVELOPMENT ("R&D")

The Company's independently developed innovative domestic medical device products will maintain the competitive strength of the Company and also provide more effective treatments to patients around the world. In the first half of 2026, the Company continuously strengthened its innovation capabilities and accelerated the development of products, so as to maintain its industry leading position.

During the six months ended 30 June 2026, we have achieved the following milestones in the R&D field:

- Iliac Bifurcation Device (consisting of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System) and Peripheral High Pressure Balloon Dilatation Catheter have obtained the National Medical Products Administration ("NMPA") certification;

- G-iliac™ Iliac Bifurcation Stent Graft System and SilverFlow™ Internal Iliac Stent Graft System have obtained the CE MDR (Medical Device Regulation) certification;

- Cera™ PFO Occluder, CeraFlex™ PFO Occluder, FuStar™ Steerable Introducer, SeQure™ Snare System and SteerEase™ Introducer have obtained the CE MDR certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification;

- Cera™ PFO Occluder, Yuranos™ Pro Abdominal Aortic Stent Graft System and Constraining Structure PTA Balloon Catheter, etc. are pending registration approval in China;

- Aortic Stent Graft System (consisting of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System, Thoracoabdominal Artery Stent Graft System (consisting of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System, G-Branch™ AE Main Body Extension Stent Graft System, G-Branch™ AAA Bifurcated Stent Graft System and G-Branch™ IE Iliac Extension Stent Graft System) and Aortic Arch Stent Graft System (consisting of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System) are pending registration approval of CE certification;

- X-Clip™ Mitral Valve Clip System and Nitinol Patent Ductus Arteriosus Occluder are currently at the stage of pre-registration clinical enrollment in China;

- CS™ Concave Supra-arch Branched Stent-Graft System and SureCham™ Aortic Arch Single Branch Stent Graft System (consisting of the Aortic Arch Stent Graft System and Aortic Branch Stent Graft System) have completed pre-marketing clinical enrollment and are currently under clinical follow-up in China;

- IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe, and its CE registration application has been submitted;

- IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the five-year follow-up of the phase I clinical study and the three-year follow-up of the phase II and III clinical study, further confirming its safety and efficacy. Additionally, its CE and NMPA registration application have been submitted; and

- CS™ Concave Supra-arch Branched Stent-Graft System has been admitted into the NMPA Special Examination and Approval Procedure for Innovative Medical Devices, which is the 17th product of the Company to have obtained admission to the Procedure.

INTELLECTUAL PROPERTY RIGHTS

Intellectual property is an important intangible asset of the Group and also an internal driving force to improve our core competitiveness in the medical device market. During the six months ended 30 June 2026, the Group has filed 50 patent applications and separately, 171 patents were successfully registered. As at 30 June 2026, the Group has filed a total of 2,608 valid patent applications, of which 1,370 patents were registered and valid.

FINANCIAL REVIEW

OVERVIEW

The following discussion is based on, and should be read in conjunction with, the financial information and the notes appended thereto included in this interim results announcement.

REVENUE

The revenue of the Group was approximately RMB600.8 million for the six months ended 30 June 2026, with a decrease of approximately RMB75.9 million or approximately 11.2% as compared with the revenue of approximately RMB676.7 million for the corresponding period of 2025. The decrease was mainly due to the decrease of revenue from sales of structural heart diseases occluders and cardiac pacemakers.

Revenue from the structural heart diseases business

The turnover contributed by the structural heart diseases business for the six months ended 30 June 2026 was approximately RMB200.1 million (corresponding period of 2025: approximately RMB271.5 million), representing a decrease of approximately 26.3% as compared with the corresponding period of 2025.

We have diversified our product portfolio to cover a wide spectrum of the structural heart diseases business, including but not limited to, LAA occluders and three generations of congenital heart diseases occluders namely HeartR, Cera and CeraFlex. As compared with the corresponding period of 2025, the revenue generated from the sales of LAA occluders decreased by approximately 53.8%, and congenital heart diseases occluders decreased by approximately 8.9%.

Revenue from the peripheral vascular diseases business

The turnover contributed by the peripheral vascular diseases business for the six months ended 30 June 2026 was approximately RMB400.7 million (corresponding period of 2025: approximately RMB391.7 million), representing an increase of approximately 2.3% as compared with the corresponding period of 2025.

The products offered in the peripheral vascular diseases business mainly include vena cava filters, Thoracic Aortic Aneurysm stent grafts, Abdominal Aortic Aneurysm stent grafts, Iliac Artery Bifurcation stent grafts, Aortic stent graft systems, Aortic Arch stent graft systems and Thoracoabdominal Aortic stent graft systems. As compared with the corresponding period of 2025, the revenue generated from the sales of stent grafts increased by approximately 2.9%, and the revenue generated from the sales of vena cava filters increased by approximately 2.6%.

Revenue from the cardiac pacing and electrophysiology business

The turnover contributed by the cardiac pacing and electrophysiology business for the six months ended 30 June 2026 was nil (corresponding period of 2025: approximately RMB13.5 million).

GROSS PROFIT AND GROSS PROFIT MARGIN

Gross profit of the Group decreased by approximately 6.4% from approximately RMB497.8 million for the six months ended 30 June 2025 to approximately RMB465.9 million for the six months ended 30 June 2026.

Gross profit margin increased 3.9 percentage points from approximately 73.6% for the six months ended 30 June 2025 to approximately 77.5% for the six months ended 30 June 2026. The increase was mainly due to the change in sales portfolios, resulting from sales contributions from the newly launched products with higher gross profit margins, coupled with the decrease in sales of lower-margin cardiac pacemakers.

OTHER INCOME, EXPENSES, GAINS AND LOSSES

Other income, expenses, gains and losses decreased from gains of approximately RMB50.4 million for the six months ended 30 June 2025 to losses of approximately RMB19.7 million for the six months ended 30 June 2026. The decrease was mainly due to the fluctuation of foreign exchange rates, which resulted in net exchange losses of approximately RMB32.8 million for the six months ended 30 June 2026, as compared with net exchange gains of approximately RMB24.0 million recorded in the corresponding period of 2025.

FINANCIAL ASSETS AT FVTPL

On 25 May 2018, the Group invested USD6.0 million (equivalent to approximately RMB38.2 million) to subscribe for the partnership interest of approximately 9.69% in Ally Bridge Group Innovation Capital Partners III, L.P., a private equity fund established in the Cayman Islands. The 2018 Equity Fund principally invests in securities or assets of companies in the healthcare industry, with a particular focus on cross-border innovative late-stage venture opportunities and crossover investments. The fair value of our investment in the 2018 Equity Fund as at 30 June 2026 amounted to approximately RMB10.4 million (31 December 2025: approximately RMB8.9 million), representing approximately 0.2% (31 December 2025: approximately 0.2%) of the Company's total assets. Based on the cumulative net distributions of approximately RMB57.8 million by the fund to the Group, coupled with the outlook of the healthcare industry, the Company is optimistic on the prospects of its investments in the 2018 Equity Fund.

On 8 January 2021, the Group invested RMB10.0 million to subscribe for a share of the private securities investment fund. The fair value of this investment as at 30 June 2026 amounted to approximately RMB21.7 million (31 December 2025: approximately RMB16.2 million), representing approximately 0.5% (31 December 2025: approximately 0.3%) of the Company's total assets.

On 24 October 2022, the Group entered into a subscription agreement with certain independent third parties pursuant to which the Group agreed to subscribe in Ally Bridge Group Global Life Science Capital Partners V, L.P., as a limited partner, for an aggregate consideration of USD20.0 million (equivalent to approximately RMB144.4 million) in cash. The purposes of the 2022 Equity Fund are to seek capital appreciation primarily by acquiring, holding and disposing of securities, independently or with others, primarily in non-listed or, sometimes, listed entities involved in the healthcare industry, with a particular focus on leading innovative technologies. The fair value of our investment in the 2022 Equity Fund as at 30 June 2026 amounted to approximately RMB191.8 million (31 December 2025: approximately RMB196.0 million), representing approximately 4.0% (31 December 2025: approximately 3.9%) of the Company's total assets.

On 28 November 2023, the Group invested RMB50.0 million to subscribe for a share of the private securities investment fund. The fair value of this investment as at 30 June 2026 amounted to approximately RMB29.0 million (31 December 2025: approximately RMB32.7 million), representing approximately 0.6% (31 December 2025: approximately 0.7%) of the Company's total assets.

On 6 June 2025, the Group entered into a series of agreements through Lifetech Shenzhen, to make a cash investment in Affector Medtech, for a total consideration of RMB150.0 million. Upon completion of all stages of the investment, Lifetech Shenzhen will hold 30% equity interest in Affector Medtech. As of 30 June 2026, Lifetech Shenzhen has completed the first stage of capital injection, for a consideration of RMB100.0 million in cash and holds a 22.22% equity interest in Affector Medtech. The fair value change in relation to the financial assets for the six months ended 30 June 2026 is insignificant. The fair value of the Group's investment in Affector Medtech as at 30 June 2026 amounted to RMB100.0 million (31 December 2025: RMB100.0 million), representing approximately 2.1% (31 December 2025: approximately 2.0%) of the Company's total assets.

The aggregate unrealised foreign exchange losses in financial assets at FVTPL was approximately RMB6.4 million for the six months ended 30 June 2026 (corresponding period of 2025: losses of approximately RMB0.9 million), and the aggregate gains from changes in fair value of financial assets at FVTPL was approximately RMB5.5 million (corresponding period of 2025: gains of approximately RMB10.7 million).

The investments are classified as financial assets at FVTPL in accordance with IFRS 9. In the opinion of the Directors, the above investments are held for long-term strategic investment purposes and, as such, the above investments are classified as non-current assets.

SELLING AND DISTRIBUTION EXPENSES

Selling and distribution expenses decreased by approximately 29.0% from approximately RMB250.9 million for the six months ended 30 June 2025 to approximately RMB178.1 million for the six months ended 30 June 2026. The decrease was mainly due to the decrease in staff costs, of which the share-based payment expenses decreased to approximately RMB49.6 million for the six months ended 30 June 2026 as compared with approximately RMB128.4 million for the corresponding period of 2025.

ADMINISTRATION EXPENSES

Administration expenses increased by approximately 24.3% from approximately RMB118.4 million for the six months ended 30 June 2025 to approximately RMB147.2 million for the six months ended 30 June 2026. This increase was mainly due to the increase in the transaction expenses in connection with a proposed transaction involving the conditional acquisition of equity interest in Starway and the issue of convertible bonds, which the Board has resolved not to proceed with, amounting to approximately RMB25.3 million (corresponding period of 2025: nil).

R&D EXPENSES

R&D expenses increased by approximately 15.5% from approximately RMB114.5 million for the six months ended 30 June 2025 to approximately RMB132.2 million for the six months ended 30 June 2026. In addition, during the current period, approximately RMB34.9 million (corresponding period of 2025: approximately RMB41.5 million) was capitalised as development expenditure. Taking into account such capitalised expenditure, R&D costs increased by approximately 7.1% from approximately RMB156.0 million for the six months ended 30 June 2025 to approximately RMB167.1 million for the six months ended 30 June 2026. This increase was mainly due to the commencement of amortisation of capitalised development costs for newly registered products, which resulted in an increase in amortisation of intangible assets, as well as an increase in overseas registration fees.

OPERATING PROFIT AND LOSS

During the six months ended 30 June 2026, excluding certain non-recurring items as set out below, the Group recorded an operating profit of approximately RMB137.9 million, as compared with the operating profit of approximately RMB248.0 million for the corresponding period of 2025, representing a decrease of approximately 44.4%. The decrease was mainly due to (i) a decrease in revenue, which amounted to approximately RMB75.9 million; and (ii) a decrease in net exchange gains, which amounted to approximately RMB56.8 million (net exchange losses of approximately RMB32.8 million for the six months ended 30 June 2026, as compared with net exchange gains of approximately RMB24.0 million in the corresponding period of 2025).

The above-mentioned non-recurring items include (i) the other losses arising from financial assets at FVTPL of approximately RMB0.8 million for the six months ended 30 June 2026 (corresponding period of 2025: gains of approximately RMB9.9 million); (ii) the share-based payment expenses of approximately RMB123.1 million for the six months ended 30 June 2026 (corresponding period of 2025: approximately RMB193.5 million); and (iii) the transaction expenses in connection with a proposed transaction involving the conditional acquisition of equity interest in Starway and the issue of convertible bonds, which the Board has resolved not to proceed with, amounting to approximately RMB25.3 million (corresponding period of 2025: nil). Taking into account the effects of such non-recurring items, the operating loss for the six months ended 30 June 2026 was approximately RMB11.3 million, representing a decrease of approximately 117.5%, as compared with operating profit of approximately RMB64.4 million for the six months ended 30 June 2025.

SHARE OF RESULTS IN ASSOCIATES

The Group's share of losses in associates was approximately RMB3.0 million for the six months ended 30 June 2026 (corresponding period of 2025: gains of approximately RMB5.3 million).

FINANCE INCOME AND FINANCE COSTS

Finance income decreased by approximately 73.8% from approximately RMB10.3 million for the six months ended 30 June 2025 to approximately RMB2.7 million for the six months ended 30 June 2026.

Finance costs increased by approximately 40.7% from approximately RMB135,000 for the six months ended 30 June 2025 to approximately RMB190,000 for the six months ended 30 June 2026.

FINANCIAL LIABILITIES AT FVTPL

In 2020, Lifetech Shenzhen, a wholly-owned subsidiary of the Company, entered into Series A Agreement with certain independent third parties; in 2023 entered into Series B Agreement with certain independent third parties, and in June 2026 entered into Series C Agreement with certain independent third parties for issuance of shares of Biotyx Medical. Pursuant to the above mentioned Series A, Series B and Series C Agreements, if Biotyx Medical is unable to meet certain specified conditions under agreed timeframe, some holders of these shares will have the right to require Biotyx Medical to redeem all of their shares at the predetermined consideration. Accordingly, such shares are classified as a financial liability.

The fair value change in relation to the financial liabilities for the six months ended 30 June 2026 is insignificant.

The fair value of financial liabilities at FVTPL as at 30 June 2026 amounted to approximately RMB576.8 million (31 December 2025: approximately RMB576.8 million).

Additional information is set out in Note 15 to the condensed consolidated financial statements in this interim results announcement.

INCOME TAX

Income tax decreased from approximately RMB38.0 million for the six months ended 30 June 2025 to approximately RMB36.5 million for the six months ended 30 June 2026, which was mainly due to decreased assessable income.

NET PROFIT AND LOSS

Net profit attributable to owners of the Company for the six months ended 30 June 2026, excluding certain non-recurring items as set out below, was approximately RMB114.8 million as compared with the net profit amounting to approximately RMB238.5 million for the six months ended 30 June 2025, representing a decrease of approximately 51.9%. The decrease was mainly due to (i) a decrease in revenue, which amounted to approximately RMB75.9 million; and (ii) a decrease in net exchange gains, which amounted to approximately RMB56.8 million (net exchange losses of approximately RMB32.8 million for the six months ended 30 June 2026, as compared with net exchange gains of approximately RMB24.0 million in the corresponding period of 2025).

The above-mentioned non-recurring items include (i) the other losses arising from financial assets at FVTPL of approximately RMB0.8 million for the six months ended 30 June 2026 (corresponding period of 2025: gains of approximately RMB9.9 million); (ii) the share-based payment expenses of approximately RMB123.1 million for the six months ended 30 June 2026 (corresponding period of 2025: approximately RMB193.5 million); and (iii) the transaction expenses in connection with a proposed transaction involving the conditional acquisition of equity interest in Starway and the issue of convertible bonds, which the Board has resolved not to proceed with, amounting to approximately RMB25.3 million (corresponding period of 2025: nil). Taking into account the effects of such non-recurring items, the net loss attributable to owners of the Company for the six months ended 30 June 2026 was approximately RMB34.3 million, representing a decrease of approximately 162.3% as compared with net profit of approximately RMB55.1 million for the six months ended 30 June 2025.

EQUITY INSTRUMENTS AT FVTOCI

On 21 September 2022, the Group entered into a subscription agreement with Jenscare Scientific pursuant to which the Group agreed to subscribe for shares of Jenscare Scientific upon its initial public offering, as a cornerstone investor, for an aggregate consideration of USD20.0 million (equivalent to approximately RMB143.9 million) in cash with the price of HKD27.8 per share. The fair value of the equity security in the listed entity is determined based on the closing prices quoted in active markets. They are accounted for using their fair values based on quoted market prices. The fair value of this investment as at 30 June 2026 amounted to approximately RMB35.6 million (31 December 2025: approximately RMB45.4 million), representing approximately 0.7% of the Company's total assets (31 December 2025: approximately 0.9%).

The unrealised foreign exchange losses in equity instruments at FVTOCI was approximately RMB1.7 million for the six months ended 30 June 2026 (corresponding period of 2025: losses of approximately RMB0.7 million), and the losses from changes in fair value of equity instruments at FVTOCI was approximately RMB8.1 million (corresponding period of 2025: gains of approximately RMB27.0 million).

Jenscare Scientific is a medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. Established in 2011, it has developed a series of treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure. The shares of Jenscare Scientific are listed on the Stock Exchange (stock code: 9877). The Group held 5,646,600 H shares in Jenscare Scientific, representing approximately 1.8% of its total issued share capital as at 30 June 2026.

The investment is classified as equity instruments at FVTOCI in accordance with IFRS 9. Additional information in relation to the investment is set out in Note 11 to the condensed consolidated financial statements in this interim results announcement. In the opinion of the Directors, the above investment is held for long-term strategic investment purposes and, as such, the above investment is classified as non-current asset.

LIQUIDITY AND FINANCIAL RESOURCES

During the six months ended 30 June 2026, the Group mainly financed its operations with its own working capital.

The Group recorded total current assets of approximately RMB2,070.3 million as at 30 June 2026 (31 December 2025: approximately RMB2,325.1 million) and total current liabilities of approximately RMB844.8 million as at 30 June 2026 (31 December 2025: approximately RMB1,479.4 million). As at 30 June 2026, the total current liabilities of the Group primarily included trade and other payables amounting to approximately RMB788.9 million (31 December 2025: approximately RMB841.1 million). Other payables primarily included accrued expenses of approximately RMB161.0 million (31 December 2025: approximately RMB153.2 million) primarily in relation to clinical expenses and exhibition expenses, as well as accrued payroll and bonus of approximately RMB87.6 million (31 December 2025: approximately RMB109.3 million).

Trade receivables in terms of debtor turnover days was 43 days (31 December 2025: 39 days), and trade payables in terms of creditor turnover days was 115 days (31 December 2025: 74 days).

The current ratio (calculated by dividing the total current assets by the total current liabilities) of the Group was approximately 2.45 as at 30 June 2026 (31 December 2025: approximately 1.57).

BORROWINGS

On 18 March 2026, Biotyx Medical, acting as the borrower, entered into a loan agreement with Bank of China Co., Ltd. Shenzhen Longhua Sub-branch (the "Lender"), pursuant to which the Lender agreed to lend a loan in the amount of RMB5.0 million to Biotyx Medical for a term of twelve months at interest rate of 2.8%.

As at 30 June 2026, the bank borrowing was RMB5.0 million (31 December 2025: nil) and the interest incurred therefrom was approximately RMB0.04 million for the six months ended 30 June 2026 (corresponding period of 2025: nil) which was recognised as finance costs.

CASH AND CASH EQUIVALENTS

As at 30 June 2026, the Group's cash and cash equivalents were approximately RMB953.8 million, representing an increase of approximately 32.6% from approximately RMB719.3 million as at 31 December 2025. The cash and cash equivalents of the Group were mainly denominated in Renminbi, US dollars and Euros.

GEARING RATIO

As at 30 June 2026, the gearing ratio of the Group (calculated based on the ratio of total bank borrowings to total equity) was approximately 0.2% (31 December 2025: zero).

CAPITAL STRUCTURE

Total equity attributable to equity holders of the Company amounted to approximately RMB3,319.4 million as at 30 June 2026 as compared with approximately RMB3,512.6 million as at 31 December 2025.

TREASURY POLICY

The Directors will continue to follow a prudent policy in managing the Group's financial resources such as cash, with the objective of maintaining a strong and healthy liquidity position to ensure that the Group is well-placed to seize future growth opportunities whenever such opportunities arise.

PROPERTY HELD

On 26 June 2019, Dongguan LifeTech Medical Co., Ltd. (東莞市先健醫療有限公司) ("Dongguan LifeTech"), a wholly-owned subsidiary of the Company entered into a land use right transfer contract with the Dongguan Natural Resources Bureau (東莞市自然資源局) for the acquisition of land use right of a land which has a site area of 43,604 square meters located at the southeast of the intersection of South 1 Road and South 8 Road in eastern Songshan Lake, Dongguan, Guangdong, the PRC (the "Land"). The land use right is wholly owned by the Group which was acquired at a total consideration of approximately RMB43.6 million.

On 24 April 2020, Dongguan LifeTech entered into a construction contract with China Construction Second Engineering Bureau Limited for the construction of an industrial park above the Land. The industrial park covers a total site area of approximately 43,604 square meters and can cater for the Group's day-to-day business and operational needs in Dongguan and nearby regions. The contract price for the construction works is up to a maximum aggregate amount of RMB620.0 million. The construction contract was approved by independent shareholders by way of poll at the extraordinary general meeting of the Company held on 30 June 2020. For further details and information, please refer to the Company's announcements dated 26 June 2019, 24 April 2020 and 30 June 2020 and the circular dated 9 June 2020.

In May 2023, the Company had obtained property ownership certificates of all buildings and basements. As at 30 June 2026, a portion of the total gross floor area of the industrial park has been allocated for the Company's own operations and external tenant leasing, with the remaining area reserved for future allocation.

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

On 22 May 2026, the Company entered into framework agreement with AUT-VII HK Holdings Limited ("AUT-VII HK"), pursuant to which the Company has conditionally agreed to acquire, and AUT-VII HK has conditionally agreed to sell, approximately 96.46% of the equity interest in Starway. On 20 July 2026, the Board has resolved not to proceed with the proposed acquisition of Starway.

Save as disclosed above, there were no other material acquisitions and disposals of subsidiaries, associates and joint ventures during the six months ended 30 June 2026.

SIGNIFICANT INVESTMENTS AND FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in this interim results announcement, there were no significant investments held by the Company with a value greater than 5% of its total assets as at 30 June 2026, nor was there any plan authorised by the Board for other material investments or additions of capital assets as at the date of this interim results announcement.

The Group's investment strategy for significant investments is to identify investment opportunities with growth potential within the healthcare industry and seek opportunities for strategic cooperation. We hold our investments in equity instruments. Our investment objective is to form long-term strategic partnerships with companies in the medical industry with the potential of enriching our product lines and expanding our business scale, thereby maximising shareholders' interests and value.

CONTINGENT LIABILITIES

The Group did not have any significant contingent liabilities as at 30 June 2026.

FINANCIAL INSTRUMENT

As at 30 June 2026, the Group did not have any outstanding hedge contracts or financial derivative instruments.

CAPITAL EXPENDITURE

During the six months ended 30 June 2026, the capital expenditure of the Group for property, plant and equipment, construction in progress, intangible assets, right-of-use assets and deposits for property, plant and equipment amounted to approximately RMB50.5 million (corresponding period of 2025: approximately RMB56.7 million).

FOREIGN EXCHANGE EXPOSURE

During the six months ended 30 June 2026, the Group primarily conducted its operations in both Asia and Europe. The revenue generated from Asia (excluding China's mainland) and Europe accounted for approximately 10.3% and 12.6%, respectively, of the Group's total revenue for the six months ended 30 June 2026 (corresponding period of 2025: approximately 11.4% and 11.0%, respectively). The operational results and financial condition of the Group may be affected by fluctuations in exchange rates involving the currencies used in its business transactions.

Although the Group did not implement any hedging strategies to mitigate this exposure during the Reporting Period, the management closely monitored foreign currency exposure to maintain net exposure at an acceptable level. The Group expects that exchange rate fluctuations will not have a material adverse effect on its operations in the foreseeable future. However, the Group will consider hedging significant foreign currency exposure should the need arise.

CHARGES ON GROUP ASSETS

As at 30 June 2026, the Group did not have any charges on its assets.

CAPITAL COMMITMENT

As at 30 June 2026, the Group's capital expenditure contracted for but not provided in the condensed consolidated financial statements amounted to approximately RMB3.4 million (31 December 2025: approximately RMB15.8 million).

SEGMENT INFORMATION

During the six months ended 30 June 2026, the revenue of the Group was principally generated from the structural heart diseases business, the peripheral vascular diseases business and the cardiac pacing and electrophysiology business. An aging population, urbanisation and the continuous improvement of health awareness by the public, are all factors which contribute to the steady growth of the healthcare industry. These trends, along with our R&D efforts, suggest that there will be an increased demand for our products in the future, thus leading to business growth.

STRUCTURAL HEART DISEASES BUSINESS

The Company has developed four generations of congenital heart diseases occluders to satisfy various patients' needs, and to achieve differentiated marketing strategies. At the same time, we continue to upgrade the LAA occluder to meet the growing treatment demand with innovative technology. Driven by a large number of patients with atrial fibrillation around the world, the global market for the LAA occluder is expected to keep growing in the future.

PERIPHERAL VASCULAR DISEASES BUSINESS

The Company provides patients with technology-leading systemic and comprehensive interventional medical devices treatment solutions of peripheral vascular diseases. Among those products, the market shares of vena cava filters and stent grafts occupy a leading position in the domestic market. An aging population, increase in diseases detection rate and expansion of product applications are factors that would help drive the growth of market demand for these products.

CARDIAC PACING AND ELECTROPHYSIOLOGY BUSINESS

The Company offers innovative solutions for the diagnosis and treatment of cardiac arrhythmias.

Please refer to the paragraph headed "Financial Review – Revenue" above for the financial performance of these business segments. Financial information related to these aspects is presented in Note 4 to the condensed consolidated financial statements in this interim results announcement.

EMPLOYEES AND REMUNERATION POLICY

As at 30 June 2026, the Group had 1,251 full-time employees (31 December 2025: 1,240) and three executive Directors (31 December 2025: five). Total staff costs, including share-based payment expenses, amounted to approximately RMB317.5 million for the six months ended 30 June 2026 (corresponding period of 2025: approximately RMB359.6 million), of which Directors' emoluments were approximately RMB96.1 million (corresponding period of 2025: approximately RMB22.3 million).

The employees of the Group who operate in the PRC are members of a state-managed retirement benefits scheme operated by the PRC government under which the employees are entitled to a monthly pension after retirement. The Group is required to contribute a certain percentage of employee's salaries to the retirement benefits scheme to fund the benefits. The only obligation of the Group with respect to the retirement benefits scheme is to make the aforementioned specified contributions. The Group operates the Mandatory Provident Fund Scheme for all qualifying employees in Hong Kong. Contributions to these schemes are expensed as incurred. During the six months ended 30 June 2026, the total cost paid or payable in relation to contributions to the retirement benefits scheme was approximately RMB18.9 million (corresponding period of 2025: approximately RMB18.7 million). Forfeited contributions (by the Group on behalf of the employees who leave the aforesaid schemes prior to vesting fully in such contributions) may not be used by the Group to reduce the existing level of contributions.

The Group's remuneration policies were determined with reference to the performance, qualification and working experience of individual employees, as well as the results of the Group and the market conditions. The benefits provided by the Group to its employees include discretionary bonus, transportation and meal subsidies, basic and group medical insurance, work injury insurance, unemployment insurance, annual physical examination, share options, etc. We have a fair and effective performance appraisal system and schemes designed to motivate and reward employees at all levels for their performance and achievements. The Company adopted a share option scheme on 22 October 2011, which was subsequently amended by unanimous written resolutions of the Board on 5 May 2015. On 17 September 2021, as the number of share options which may be granted under such share option scheme had reached its limit and would soon expire, the Company terminated such share option scheme and adopted a new share option scheme to provide incentives for employees of the Group and other eligible participants thereunder. The Company has adopted a share award scheme on 28 December 2018, which was subsequently amended by unanimous written resolutions of the Board on 29 April 2019. The Company also adopted another share award scheme on 3 March 2022.

Employees are the cornerstone of enterprise development, and the Group is committed to providing all employees with a safe and comfortable working environment, opportunities of equal employment, trainings and career development, such as orientation programmes for new employees, regulation-related trainings and position skills trainings. The Group has also established a labour union to safeguard the legitimate rights of its employees and to further promote the Group's sustainable, stable and healthy development.

THE 2020 PLACING

On 11 December 2020, the Company completed a placing of an aggregate of 287,320,000 new ordinary shares of the Company, with an aggregate nominal value of USD359.15, at a placing price of HKD3.2368 per share pursuant to a placing agreement dated 4 December 2020 (the "2020 Placing").

Pursuant to the 2020 Placing, an aggregate of 287,320,000 new ordinary shares, representing approximately 6.21% of the issued share capital of the Company as enlarged by the allotment and issue of the new shares immediately after the completion of the 2020 Placing, have been successfully placed to not less than six placees who and whose ultimate beneficial owner(s), to the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, are independent of the Company. None of the placees and their respective ultimate beneficial owners have become a substantial shareholder (as defined under the Listing Rules) of the Company as a result of the placing.

The placing price of HKD3.2368 per placing share represents:

(i) a discount of approximately 11.6% to the closing price of HKD3.660 per share of the Company as quoted on the Stock Exchange on 3 December 2020, being the trading day prior to the date of the placing agreement;

(ii) a discount of approximately 9.3% to the average closing price of approximately HKD3.570 per share of the Company as quoted on the Stock Exchange for the five consecutive trading days immediately prior to the date of the placing agreement; and

(iii) a discount of approximately 2.3% to the average closing price of approximately HKD3.313 per share of the Company as quoted on the Stock Exchange for the ten consecutive trading days immediately prior to the date of the placing agreement.

The net placing price (after deducting the costs and expenses incurred for the 2020 Placing) was approximately HKD3.2366 per placing share. The net proceeds raised from the 2020 Placing were approximately HKD930.0 million.

As at 30 June 2026, approximately HKD380.6 million brought forward from the net proceeds received by the Company from the 2020 Placing remained unutilised.

As at 30 June 2026, the details and usage of the proceeds from the 2020 Placing were as follows:

Intended use of proceeds	**Approximate allocation of net proceeds as previously disclosed (HKD in million)**	**Approximate amount of net proceeds unutilised as at 31 December 2025 (HKD in million)**	**Approximate utilisation of proceeds during the six months ended 30 June 2026 (HKD in million)**	**Approximate amount of net proceeds unutilised as at 30 June 2026 (HKD in million)**	**Expected timeline for utilisation of unutilised proceeds**
Repayment of certain bank borrowings of the Group	406.0	—	—	—	Fully utilised
Funding potential business development involving a new overseas clinical project	465.0	384.9	4.3	380.6	To be applied in the second half of 2026 (HKD20.0 million) and 2027 (HKD360.6 million) subject to adjustments (if any)
General working capital of the Group	59.0	—	—	—	Fully utilised
Total	**930.0**	**384.9**	**4.3**	**380.6**	

Approximately HKD4.3 million of the net proceeds of the 2020 Placing had been utilised during the six months ended 30 June 2026 in accordance with the intended use of proceeds. There has been no change in the intended use of net proceeds. The unutilised net proceeds from the 2020 Placing would be brought forward to the next financial period/year and will be gradually utilised in accordance with the above intended purposes.

The Directors consider that the 2020 Placing represented an opportunity to raise capital while broadening its capital and shareholder base. The Directors were of the view that the 2020 Placing would strengthen the financial position of the Company and provide working capital to the Company.

For further details, please refer to the Company's announcements dated 4 December 2020 and 11 December 2020.

EVENTS AFTER THE REPORTING PERIOD

Reference is made to the Company's announcement dated 22 May 2026 regarding a transaction involving the proposed acquisition of equity interest in Starway and the proposed issue of convertible bonds. Following the publication of the announcement, the Company negotiated with AUT-VII HK on the definitive transaction documents. As the two parties were unable to reach a consensus, after prudent consideration, the Board resolved not to proceed with the major transaction on 20 July 2026, as disclosed in the Company's announcement dated 20 July 2026.

Reference is made to the Company's announcement dated 12 August 2026. Mr. FANG Yu, an executive Director, has been appointed as an authorised representative of the Company with effect from 12 August 2026.

Save as disclosed above, there were no other significant events affecting the Group after 30 June 2026.

FUTURE PROSPECTS

The global medical device industry continues to present significant growth opportunities, driven by demographic shifts, technological advancements, and increasing healthcare demands. Although the expansion of the coverage of China's centralized procurement policies has exerted pricing pressure on certain medical device products, it has also accelerated industry consolidation, prompting companies to place greater emphasis on innovation and differentiated competition. Leveraging strong R&D capabilities, a diversified product portfolio, and a growing global presence, the Company has established a resilient competitive advantage, enabling us to proactively capture industry opportunities and drive sustained and stable business growth. Despite the volatility of the internal and external environment during the Reporting Period, which had certain impact on the Group's short-term financial performance, the Group's core business remained stable, with continuous optimization of its product sales mix and orderly progress across all work streams, laying a solid foundation for sustainable growth in the future.

Looking ahead, the Company will continue to focus on advancing its robust R&D pipeline, accelerating product commercialization both domestically and internationally, and expanding its global market presence. We remain committed to disciplined capital allocation and operational efficiency to navigate the evolving market dynamics. The Company will continue to invest in innovation and technology to address unmet clinical needs, while strengthening its competitive position in the global medical device industry.

The Company is confident in its ability to navigate both challenges and opportunities in the evolving healthcare landscape. By staying true to our core strengths in innovation and execution, we are well-positioned to deliver sustainable long-term growth and reinforce our leadership in the global medical device industry. We remain committed to creating value for patients, healthcare providers, and shareholders through our continued focus on technological advancement and operational excellence.

OTHER INFORMATION

INTERIM DIVIDEND

The Directors did not recommend the payment of any interim dividend for the six months ended 30 June 2026 (corresponding period of 2025: nil).

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2026, there were no purchase, sales or redemptions of the Company's listed securities by the Company or any of its subsidiaries.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company is committed to achieving high standards of corporate governance to safeguard the interests of its shareholders (the "Shareholders") and enhance its corporate value. The Company has applied the principles as set out in the Corporate Governance Code (the "CG Code") contained in Appendix C1 to the Listing Rules as its own code of corporate governance and confirms that it has complied with all code provisions of the CG Code during the six months ended 30 June 2026, save for the deviation from code provision C.2.1 of the CG Code as mentioned below.

According to code provision C.2.1 of the CG Code, the roles of the Chairman and Chief Executive Officer should be separate and should not be performed by the same individual. Subsequent to the resignation of former Chief Executive Officer of the Company, Mr. XIE Yuehui, Chairman of the Board, has been appointed to act as the Chief Executive Officer of the Company on 2 March 2015. Accordingly, the roles of the Chairman of the Board and the Chief Executive Officer are performed by the same individual. Although the dual roles of the Chairman and Chief Executive Officer is a deviation from the code provision C.2.1 of the CG Code, the Board believes that vesting the roles of both Chairman and Chief Executive Officer in an experienced and qualified person such as Mr. XIE Yuehui provides the Company with strong and consistent leadership while allowing for effective and efficient planning and implementation of business decisions and strategies.

The Board reviews the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") as set out in Appendix C3 to the Listing Rules as its own code of conduct for dealing in securities of the Company by the Directors on terms no less exacting than the required standard set out in the Model Code.

Having made specific enquiries with all the Directors, the Company confirmed that all members of the Board complied with the Model Code during the six months ended 30 June 2026.

Senior management, executives and staff members who, because of their offices in the Company, are likely to possess inside information, have also been requested to comply with the provisions of the Model Code. No incident of non-compliance with the Model Code by such employees was noted by the Company during the six months ended 30 June 2026.

AUDIT COMMITTEE AND REVIEW OF INTERIM RESULTS

The Board has established an audit committee (the "Audit Committee") in accordance with the corporate governance requirements of listed companies of the Stock Exchange. As at the date of this interim results announcement, the Audit Committee consists of three members, all of whom are independent non-executive Directors, namely Ms. CHEN Dongxia who possesses appropriate professional qualifications to serve as its Chairlady, Mr. ZHOU Luming and Mr. JIANG Feng.

The Group's unaudited interim results for the six months ended 30 June 2026 and accounting principles have been reviewed and discussed by the Audit Committee, which was of the opinion that the preparation of such results was in compliance with the relevant accounting standards, the Listing Rules and the applicable legal requirements, and that adequate disclosure has been made.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

The interim results announcement is published on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk and the Company's website at www.lifetechmed.com. The 2026 interim report of the Company containing all the information required by the Listing Rules will be made available to the Shareholders and published on the above websites in due course.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and
Chief Executive Officer

Hong Kong, 28 August 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu being executive Directors; and Mr. ZHOU Luming, Ms. CHEN Dongxia and Mr. JIANG Feng being independent non-executive Directors.